🚀 VC round data is live in beta, check it out!
RAPT Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for RAPT Therapeutics and similar public comparables like Nurix Therapeutics, Eczacıbaşı İlaç, Harmony Biosciences, Yantai Dongcheng and more.
RAPT Therapeutics Overview
About RAPT Therapeutics
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Founded
2015
HQ
Employees
68
Website
Sectors
Financials (LTM)
EV
$2B
RAPT Therapeutics Financials
RAPT Therapeutics reported last 12-month revenue of —.
In the same LTM period, RAPT Therapeutics generated — in gross profit and had net loss of ($89M).
Revenue (LTM)
RAPT Therapeutics P&L
In the most recent fiscal year, RAPT Therapeutics reported revenue of — and net income of —.
RAPT Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Net Profit | ($89M) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
RAPT Therapeutics Stock Performance
RAPT Therapeutics has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
RAPT Therapeutics' stock price is $58.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRAPT Therapeutics Valuation Multiples
RAPT Therapeutics Financial Valuation Multiples
As of April 11, 2026, RAPT Therapeutics has market cap of $2B and EV of $2B.
Equity research analysts estimate RAPT Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
RAPT Therapeutics has a P/E ratio of (18.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/EBIT | (15.5x) | XXX | — | XXX | XXX | XXX |
| P/E | (18.9x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified RAPT Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
RAPT Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nurix Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Eczacıbaşı İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| Harmony Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Yantai Dongcheng | XXX | XXX | XXX | XXX | XXX | XXX |
| Celltrion Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
RAPT Therapeutics M&A Activity
RAPT Therapeutics acquired XXX companies to date.
Last acquisition by RAPT Therapeutics was on XXXXXXXX, XXXXX. RAPT Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by RAPT Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRAPT Therapeutics Investment Activity
RAPT Therapeutics invested in XXX companies to date.
RAPT Therapeutics made its latest investment on XXXXXXXX, XXXXX. RAPT Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by RAPT Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout RAPT Therapeutics
| When was RAPT Therapeutics founded? | RAPT Therapeutics was founded in 2015. |
| Where is RAPT Therapeutics headquartered? | RAPT Therapeutics is headquartered in United States. |
| How many employees does RAPT Therapeutics have? | As of today, RAPT Therapeutics has over 68 employees. |
| Who is the CEO of RAPT Therapeutics? | RAPT Therapeutics' CEO is Brian Russell Wong. |
| Is RAPT Therapeutics publicly listed? | Yes, RAPT Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of RAPT Therapeutics? | RAPT Therapeutics trades under RAPT ticker. |
| When did RAPT Therapeutics go public? | RAPT Therapeutics went public in 2019. |
| Who are competitors of RAPT Therapeutics? | RAPT Therapeutics main competitors are Nurix Therapeutics, Eczacıbaşı İlaç, Harmony Biosciences, Yantai Dongcheng. |
| What is the current market cap of RAPT Therapeutics? | RAPT Therapeutics' current market cap is $2B. |
| Is RAPT Therapeutics profitable? | No, RAPT Therapeutics is not profitable. |
| What is the current net income of RAPT Therapeutics? | RAPT Therapeutics' last 12 months net income is ($89M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.